Jacobio Pharmaceuticals Group Co., Ltd.

As of December 31, 2025, Jacobio Pharmaceuticals Group Co., Ltd. carries a market capitalization of 5.01B, placing it among publicly traded companies globally. Its enterprise value stands at 3.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Jacobio Pharmaceuticals Group Co., Ltd.'s next confirmed earnings release is scheduled for March 24, 2027.

As of December 31, 2025, Jacobio Pharmaceuticals Group Co., Ltd. has 787.06M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Jacobio Pharmaceuticals Group Co., Ltd. maintains a current ratio of 5.10, meaning it holds 5.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Jacobio Pharmaceuticals Group Co., Ltd.'s stock has declined approximately 30.29% over the past 52 weeks. The 50-day moving average sits at 5.75, while the 200-day moving average is 5.88.

As of December 31, 2025, Jacobio Pharmaceuticals Group Co., Ltd. holds 1.23B in cash and equivalents against 183.81M in total debt, resulting in a net debt position of -944.72M. Total book value stands at 857.63M, with working capital of 1.03B providing operational flexibility.